Phase 2 N=40 Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Maximum Tolerated Dose (MTD) of Epacadostat — 600 mg BID
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 18.8; 33.3; 30.0 Percentage of Patients
Phase 2 N=245 Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
PTSD
Primary: The Mean Change From Baseline (Visit 2) in the Total CAPS-5 Score After 12 Weeks of Treatment Evaluated at Visit 9 (Week 12). — -17.0; -19.2; -21.5 units on a scale
Phase 2 N=40 Metformin Effect on Brain Function in Insulin Resistant Elderly People
Insulin Resistance · Obesity · Obesity, Abdominal
Primary: Change From Baseline in Brain PCr/ATP Ratio as Measured by Phosphorus Magnetic Spectroscopy (31P-MRS) After 10 Months of Metformin Administration — -0.045; -0.016…
Phase 2 N=80 A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
Extranodal Natural Killer/T-Cell Lymphoma
Primary: Objective Response Rate (ORR) Assessed by IRRC — 46.2 percentage of Participants
Phase 2 N=12 Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors
Bladder Cancer
Primary: Number of Participants With Any Serious Adverse Events (SAEs) — 1 Participants
Phase 2 N=5 Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain
Cannabis · HIV Neuropathy · Pain Syndrome
Primary: Phase 1 - Numerical Pain Rating Scale (NPRS) — 2.2; 2.6; 2.8; 1.4 units on a scale
Phase 2 N=53 Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria
Chronic Kidney Diseases · Proteinuria
Primary: Change in 24-hr Proteinuria With Dapagliflozin for Six Weeks Relative to Placebo in Patients With Non-diabetic Kidney Disease and Proteinuria 500 mg/Day on Stable…
Phase 2 N=13 Energy Metabolism in Thyroidectomized Patients
Thyroid Goiter · Hypothyroidism · Thyroid Cancer
Primary: Short Term Change in Weight — 1.7; -0.76 Kilogram
Phase 2 N=529 A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Cancer of Unknown Primary Site
Primary: Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 6.14; 4.40 Months — p=0.0177
Phase 2 N=109 Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Plasma Cell Myeloma
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0 Participants
Phase 2 N=259 Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Respiratory Syncytial Virus Infection
Primary: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) — 0; 0; 0; 0 Participants
Phase 2 N=165 Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Responses With Ixazomib Citrate Alone (Arm A [Closed]), Ixazomib Citrate With Dexamethasone (Arms B + C), or With Dexamethasone and…
Phase 2 N=79 Prevention of Treatment Induced Neuropathy in Multiple Myeloma
Myeloma
Primary: The Difference Between Touch Detection Thresholds From the Sensorimotor Evaluation at Baseline and After 10 Weeks of Induction Therapy. — 0.00; 0.06; 0.08; 0.13 mN…
Phase 2 N=46 Dapagliflozin In Alzheimer's Disease
Alzheimer Disease
Primary: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine — 1.49; 1.42 Ratio